Medical Hypotheses
Volume 58, Issue 2 , Pages 136-140 , February 2002

P53 possibly upregulates the expression of CD58 (LFA-3) and CD59 (MIRL)

  • F. Sampaziotis

      Affiliations

    • Department of Histology and Embryology, Medical School, University of Athens, Greece
    • ,
  • S. Kokotas

      Affiliations

    • Department of Histology and Embryology, Medical School, University of Athens, Greece
    • ,
  • V.G. Gorgoulis

      Affiliations

    • Department of Histology and Embryology, Medical School, University of Athens, Greece
    • Molecular Oncology Unit

Received 12 February 2001 ,Accepted 5 July 2001.

References 

  1. Oren M, Prives C. p53: upstream, downstream and offstream. Review of the 8th p53 workshop, Dundee, July 5–9, 1996. Bioch et Bioph Acta. 1996;1288:R13–R19
  2. Shackelford RE, Kaufmann WK, Paules RS. Cell cycle control, checkpoint mechanisms, and genotoxic stress. Environ Health Perspect. 1999;107:5–24
  3. Schwartz D, Rotter V. p53-dependent cell cycle control: response to genotoxic stress. Semin Cancer Biol. 1998;8:325–336
  4. Alarcon R, Koumenis C, Geyer RK, Maki CG, Giaccia AJ. Hypoxia induces p53 accumulation through MDM2 down-regulation and inhibition of E6-mediated degradation. Cancer Res. 1999;59:6046–6051
  5. Royds JA, Dower SK, Qwarnstrom EE, Lewis CE. Response of tumour cells to hypoxia: role of p53 and NFkB. Mol Pathol. 1998;51:55–61
  6. Lotem J, Peled-Kamar M, Groner Y, Sachs L. Cellular oxidative stress and the control of apoptosis by wild-type p53, cytotoxic compounds, and cytokines. Proc Natl Acad Sci USA. 1996;93:9166–9171
  7. Hattori Y, Nishigori C, Tanaka T. 8-hydroxy-2′-deoxyguanosine is increased in epidermal cells of hairless mice after chronic ultraviolet B exposure. J Invest Dermatol. 1996;107:733–737
  8. Nalca A, Rangnekar VM. The G1-phase growth-arresting action of interleukin-1 is independent of p53 and p21/WAF1 function. J Biol Chem. 1998;273:30517–30523
  9. Yeung MC, Lau AS. Tumor suppressor p53 as a component of the tumor necrosis factor-induced, protein kinase PKR-mediated apoptotic pathway in human promonocytic U937 cells. J Biol Chem. 1998;273:25198–25202
  10. Gotlieb WH, Watson JM, Rezai A, Johnson M, Martinez-Maza O, Berek JS. Cytokine-induced modulation of tumor suppressor gene expression in ovarian cancer cells: up-regulated of p53 gene expression and induction of apoptosis by tumor necrosis factor-alpha. Am J Obstet Gynecol. 1994;170:1121–1128
  11. Kimura Y, Furuhata T, Urano T, Hirata K, Nakamura Y, Tokino T. Genomic structure and chromosomal localization of GML (GPI-anchored molecule-like protein), a gene induced by p53. Genomics. 1997;41:477–480
  12. Furuhata T, Tokino T, Urano T, Nakamura Y. Isolation of a novel GPI-anchored gene specifically regulated by p53: correlation between its expression and anti-cancer drug sensitivity. Oncogene. 1996;13:1965–1970
  13. Kagawa K, Inove T, Tokino T, Nakamura Y, Akiyama T. Overexpression of GML promotes radiation-induced cell cycle arrest and apoptosis. Biochem Biophys Res Commun. 1997;241:481–485
  14. Stefanova I, Hilgert I, Kristofova H, Brown R, Low MG, Horejsi V. Characterization of a broadly expressed human leucocyte surface antigen MEM-43 anchored in membrane through phosphatidylinositol. Mol Immunol. 1989;26:153–161
  15. Ueda K, Miyoshi Y, Tokino T, Watatani M, Nakamura Y. Induction of apoptosis in T98G glioblastoma cells by transfection of GML, a p53 target gene. Oncol Res. 1999;11:125–132
  16. Kagawa K, Inoue T, Tokino T, Nakamura Y, Akiyama T. Overexpression of GML promotes radiation-induced cell cycle arrest and apoptosis. Biochem Biophys Res Commun. 1997;241:481–485
  17. Kimura Y, Furuhata T, Shiratsuchi T. GML sensitizes cancer cells to Taxol by induction of apoptosis. Oncogene. 1997;15:1369–1374
  18. Meri S, Waldmann H, Lachmann PJ. Distribution of Protection (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab Invest. 1991;65:532–537
  19. Muller-Eberhard HJ. Molecular organization and function of the complement system. Annu Rev Biochem. 1988;57:321–347
  20. Varsano S, Rashkovsky L, Shapiro H, Ophir D, Mark-Bentankur T. Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance. Clin Exp Immunol. 1998;113:173–182
  21. Sugita Y, Nakano Y, Tomita M. Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement transmembrane channels. J Biochem. 1988;104:633–637
  22. Davies A, Simmons DL, Hale G. CD59, an Ly-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med. 1989;170:637–654
  23. Okada N, Harada R, Fujita T, Okada H. A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement. Int Immunol. 1989;1:205–208
  24. Wallner BP, Frey AZ, Tizard R. Primary structure of lymphocyte function-associated antigen 3 (LFA-3). J Exp Med. 1987;166:923–932
  25. Seed B. An LFA-3 cDNA encodes a phospholipid-linked membrane protein homologous to its receptor CD2. Nature. 1987;329:840–842
  26. Dustin ML, Selvaraj P, Mattaliano RJ, Springer TA. Anchoring mechanisms for LFA-3 cell adhesion glycoprotein at membrane surface. Nature. 1987;329:846–848
  27. Krensky AM, Sanchez-Madrid F, Robbins E, Nagy JA, Springer TA, Burakoff SJ. The functional significance, distribution, and structure of LFA-1, LFA-2, and LFA-3: cell surface antigens associated with CTL-target interactions. J Immunol. 1983;131:611–616
  28. Weile M, Jordan SP. Human endothelial cells effectively costimulate cytocine production by, but not differentiation of, naı̈ve CD4+ T cells. J Immunol. 1998;161:2158–2167
  29. Takami A, Zeng W, Wang H, Matsuda T, Nakao S. Cytotoxicity against lymphoblastoid cells mediated by a T-cell clone from an aplastic anaemia patient: role of CD59 on target cells. Br J Haematol. 1999;107:791–796
  30. Liversidge J, Dawson R, Hoey S, McKay D, Grabowski P, Forrester JV. CD59 and CD48 expressed by rat retinal pigment epithelial cells are major ligands for the CD2-mediated alternative pathway of T cell activation. J Immunol. 1996;156:3696–3703
  31. Menu E, Tsai BC, Bothwell ALM, Sims PJ, Bierer BE. CD59 costimulation of T cell activation: CD58 dependence and requirement for glycosylation. J Immunology. 1994;153:2444
  32. Deckert M, Kubar J, Bernard A. CD58 and CD59 molecules exhibit potentializing effects in T cell adhesion and activation. J Immunol. 1992;148:672–677
  33. Naderi S, Hofmann P, Seiter S, Tilgen W, Abken H, Reinhold U. CD2-mediated CD59 stimulation in keratinocytes results in secretion of IL-1a, IL-6, and GM-CSF: implications for the interaction of keratinocytes with intraepidermal T lymphocytes. Int J Molec Med. 1999;3:609–614
  34. Funk WD, Pak DT, Karas RH, Wright WE, Shay JW. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol. 1992;12:2866–2871
  35. El-Diery WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nature Genet. 1992;1:45–49
  36. Forsberg UH, Bazil V, Stefanova I, Schroder J. Gene for human CD59 (likely Ly-6 homologue) is located on the short arm of chromosome 11. Immunogenetics. 1989;30:188–193
  37. Holguin MH, Martin CB, Eggett T, Parker CJ. Analysis of the gene that encodes the complement regulatory protein, membrane inhibitor of reactive lysis (CD59). J Immunol. 1996;157:1659–1668
  38. Tone M, Diamond LE, Walsh LA. High level transcription of the complement regulatory protein CD59 requires an enhancer located in intron 1. J Biol Chem. 1999;274:710–716
  39. Wallich R, Brenner C, Brand Y, Roux M, Reister M, Meuer S. Gene structure, promoter characterization and basis for alternative mRNA splicing of the human CD58 gene. J Immunol. 1998;160:2862–2871
  40. Huning TG, Tiefenthaler G, Meyer Zum Buschenfelde KH, Meuer SC. Alternative pathway activation of T cells by binding of CD2 to its cell surface ligand. Nature. 1987;326:298
  41. Brittenden J, Heys SD, Ross J, Eremin O. Natural killer cells and cancer. Cancer. 1996;77:1226–1243
  42. Trincheri G. Biology of natural killer cells. Adv Immunol. 1989;47:187–375
  43. Moretta L, Ciccone E, Mingari MC, Biassoni R, Moretta R. Human natural killer cells: origin, clonality, specificity and receptors. Adv Immunol. 1994;155:341–380
  44. Lotzova E. Definition and functions of natural killer cells. Nat Immun. 1993;12:169–176
  45. Bockenstedt LK, Goldsmith MA, Dustin M, Olive D, Springer TA, Weiss A. The CD2 ligand LFAs-3 activates T cells but depends on the expression and function of the antigen receptor. J Immunol. 1988;141:1904–1911
  46. Holter W, Schwarz M, Cerwenka A, Knapp W. The role of CD2 as regulator of human T-cell cytokine production. Immunol Rev. 1996;153:107–122
  47. Tiefenthaler G, Huning T. The role of CD2/LFA-3 interaction in antigen-and mitogen- induced activation of human T cells. Int Immunol. 1989;1:169–175
  48. Foreman NK, Rill DR, Coustan-Smith E, Douglass EC, Brenner MK. Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells: potential for residual disease eradication. Br J Cancer. 1993;67:933–938
  49. Patarroyo M, Prieto J, Rincon J. Leukocyte-cell adhesion: a molecular process fundamental in leukocyte physiology. Immunol Rev. 1990;114
  50. Galandrini R, Albi N, Zarcone D, Grossi CE, Velardi A. Adhesion molecule-mediated signals regulate major histocompatibility complex-unrestricted and CD3/T cell receptor-triggered cytotoxicity. Eur J Immunol. 1992;22:2047–2053
  51. Pertussia B. Lymphokine-activated killer cells, natural killer cells and cytokines. Curr Opin Immunol. 1994;1:447–452
  52. Whiteside L, Herberman RB. The role of natural killer cells in immune surveillance of cancer. Curr Opin Immunol. 1995;7:704–710

PII: S0306-9877(01)91476-8

doi: 10.1054/mehy.2001.1476

Medical Hypotheses
Volume 58, Issue 2 , Pages 136-140 , February 2002

Article Tools